Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

New Adiponectin Test Kit Gains CE Approval

By Labmedica International staff writers
Posted on 08 Jul 2014
An automated immunoturbidimetric assay for adiponectin enables more convenient and time efficient measurement than traditional ELISA-based tests, facilitating risk assessment for developing type-2 diabetes and cardiovascular disease.

Randox Laboratories (Antrim, Northern Ireland, UK) has gained CE Approval for its recently launched biochemistry assay for adiponectin. Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD). In using latex-enhanced immunoturbidimetric technology, Randox has brought a superior option for adiponectin assessment to clinical diagnostics.

Adiponectin, a protein hormone produced and secreted exclusively by adipocytes, regulates metabolism of lipids and glucose, and influences response to insulin. Higher levels of adiponectin are correlated with increased insulin sensitivity, leading to decreased diabetes risk. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Therefore, low levels of adiponectin can be indicative of insulin resistance leading to type 2 diabetes and of cardiovascular disease (CVD). Low adiponectin levels have also been correlated with increased likelihood of a woman developing gestational diabetes in pregnancy.

The Randox Adiponectin Assay can also be used on a variety of clinical chemistry analyzer systems. It has an extensive measurement range (4–28 µg/mL), facilitating the accurate detection of reduced adiponectin levels. Two levels of adiponectin controls as well as an adiponectin calibrator are also offered, delivering a complete testing package.

Speaking after the CE approval announcement, Randox Managing Director Dr. Peter FitzGerald said, “Increasing sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease: 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of developing diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number of people becoming diabetic, while using resources most effectively.”

Related Links:

Randox Laboratories 



EUROIMMUN AG
Sekisui Diagnostics
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.